Please wait while the formulary information is being retrieved.
ABACAVIR (abacavir sulfate)
- HIV infection
300 mg tablet
- 1 tablet (300 mg) by oral route every 12 hours
20 mg/mL oral solution
- 15 milliliters (300 mg) by oral route every 12 hours
300 mg tablet
- 1 tablet (300 mg) by oral route every 12 hours
20 mg/mL oral solution
- 15 milliliters (300 mg) by oral route every 12 hours
HIV infection
- 1 tablet (300 mg) by oral route 2 times per day
- 1 tablet (300 mg) by oral route every 12 hours
- 15 milliliters (300 mg) by oral route 2 times per day
- 15 milliliters (300 mg) by oral route every 12 hours
- None
Contraindicated
- None
Severe
Moderate
- None
- Disease of liver
- HLa-B 57:01 positive
- Lactating mother
- Lactic acidosis
- Pancreatitis
- Severe hepatic disease
Contraindicated
- None
Severe
Moderate
- Coronary artery disease
- Hypertriglyceridemia
ABACAVIR (abacavir sulfate)
- HIV infection
- Headache disorder
- Diarrhea
- Dream disorder
- Fatigue
- Lipodystrophy associated with HIV
- Malaise
- Nausea
- Sleep disorder
- Vomiting
More Frequent
Severe
Less Severe
- Acute abdominal pain
- Arthralgias
- Bronchitis
- Cough
- Drug fever
- Dyspnea
- Hypersensitivity drug reaction
- Myalgias
- Pharyngitis
- Skin rash
- Chills
- Dizziness
- Hypertriglyceridemia
- Musculoskeletal pain
- Symptoms of anxiety
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Anaphylaxis
- Anemia
- Anorexia
- Edema
- Erythema multiforme
- Graves' disease
- Guillain-barre syndrome
- Hepatitis
- Hepatomegaly
- Hypotension
- Increased alanine transaminase
- Increased aspartate transaminase
- Lactic acidosis
- Multiple organ failure
- Pancreatitis
- Paresthesia
- Pneumonia
- Polymyositis
- Renal failure
- Steatosis of liver
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
Less Severe
- Depression
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Abacavir
No safety and efficacy established age < 3 months.
- 1 Day – 89 Days
- No safety and efficacy established age < 3 months.
Abacavir
- Severity Level:
2
- Additional Notes: Art preg registry data show no increased risk for major birth defects
Contraindicated
Abacavir
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- In some patients, abacavir has caused a serious (sometimes fatal) allergic reaction. Your doctor should order a blood test to measure your risk before you start this medication or take it again. If the blood test shows you are at greater risk, you should not take this medication and your doctor should discuss other treatment choices with you.<br /><br />Symptoms of an allergic reaction may include any of the following: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, fever, extreme tiredness, nausea, vomiting, diarrhea, stomach pain, muscle aches, sore throat, or cough. Get medical help right away if you experience any of these symptoms. If you have stopped taking abacavir because of an allergic reaction, you must never take any form of abacavir again, or death could result.<br /><br />Tell all of your doctors and pharmacists if you have stopped taking abacavir due to an allergic reaction. Also, properly throw away any unused abacavir. Read the warning card provided with this medication for more details.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool